Xeris Pharmaceuticals Inc. (XERS) and Axsome Therapeutics Inc. (NASDAQ:AXSM) Comparing side by side

Xeris Pharmaceuticals Inc. (NASDAQ:XERS) and Axsome Therapeutics Inc. (NASDAQ:AXSM), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of the two firms.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xeris Pharmaceuticals Inc. 8 0.00 16.93M -3.39 0.00
Axsome Therapeutics Inc. 28 0.00 23.83M -1.28 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Xeris Pharmaceuticals Inc. and Axsome Therapeutics Inc.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Xeris Pharmaceuticals Inc. 203,730,445.25% -75.9% -52.8%
Axsome Therapeutics Inc. 86,153,289.95% -564.8% -151.5%

Liquidity

The Current Ratio and Quick Ratio of Xeris Pharmaceuticals Inc. are 11.4 and 11.4 respectively. Its competitor Axsome Therapeutics Inc.’s Current Ratio is 5.7 and its Quick Ratio is 5.7. Xeris Pharmaceuticals Inc. can pay off short and long-term obligations better than Axsome Therapeutics Inc.

Analyst Ratings

Xeris Pharmaceuticals Inc. and Axsome Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Xeris Pharmaceuticals Inc. 0 0 1 3.00
Axsome Therapeutics Inc. 0 0 1 3.00

$22 is Xeris Pharmaceuticals Inc.’s average target price while its potential upside is 142.29%. Meanwhile, Axsome Therapeutics Inc.’s average target price is $48, while its potential upside is 3.09%. The results provided earlier shows that Xeris Pharmaceuticals Inc. appears more favorable than Axsome Therapeutics Inc., based on analyst view.

Insider & Institutional Ownership

Xeris Pharmaceuticals Inc. and Axsome Therapeutics Inc. has shares owned by institutional investors as follows: 67.9% and 46.3%. Xeris Pharmaceuticals Inc.’s share owned by insiders are 2.5%. Competitively, 2.2% are Axsome Therapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xeris Pharmaceuticals Inc. -4.57% 0.95% 15.73% -21.53% -35.75% -31.18%
Axsome Therapeutics Inc. -1.35% -3.66% 44.23% 206.12% 880.77% 804.26%

For the past year Xeris Pharmaceuticals Inc. had bearish trend while Axsome Therapeutics Inc. had bullish trend.

Summary

Xeris Pharmaceuticals Inc. beats Axsome Therapeutics Inc. on 6 of the 10 factors.

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.